These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 9843170

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors.
    Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E.
    Thromb Haemost; 1998 Dec; 80(6):912-8. PubMed ID: 9869160
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I.
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX.
    Valentino LA, Cooper DL, Goldstein B.
    Haemophilia; 2011 Jul; 17(4):579-89. PubMed ID: 21294815
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K, Schwarz P, Kunschak M.
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Treatment of acute bleeds with recombinant activated factor VII during immune tolerance therapy.
    Petrini P, Klementz G.
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S143-6. PubMed ID: 9819046
    [Abstract] [Full Text] [Related]

  • 15. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
    Auerswald G, Muntean W, Kemkes-Matthes B, Klamroth R, Krause M, Kurnik K, Oldenburg J, Pabinger-Fasching I, Schramm W, Zimmermann R, Zotz RB.
    Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
    [Abstract] [Full Text] [Related]

  • 16. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO, Dazzi H, von Felten A.
    Schweiz Med Wochenschr; 1995 Mar 04; 125(9):405-11. PubMed ID: 7892567
    [Abstract] [Full Text] [Related]

  • 17. Safety, efficacy and cost-effectiveness of home therapy with recombinant activated factor VII in a patient with severe haemophilia A and an anti-factor VIII inhibitor.
    Stewart AJ, Hanley JP, Ludlam CA.
    Blood Coagul Fibrinolysis; 1998 Mar 04; 9 Suppl 1():S93-5. PubMed ID: 9819036
    [Abstract] [Full Text] [Related]

  • 18. Haemostatic efficacy and safety of bolus and continuous infusion of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Results from an open-label, randomized, multicenter trial.
    Pruthi RK, Mathew P, Valentino LA, Sumner MJ, Seremetis S, Hoots WK, NovoSeven in Surgery Study Investigators.
    Thromb Haemost; 2007 Oct 04; 98(4):726-32. PubMed ID: 17938794
    [Abstract] [Full Text] [Related]

  • 19. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T, Martinowitz U, Azar-Avivi S, Zivelin A, Brutman-Barazani T, Lubetsky A, Kenet G.
    Haemophilia; 2013 Sep 04; 19(5):782-9. PubMed ID: 23659442
    [Abstract] [Full Text] [Related]

  • 20. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K, Nakatomi Y, Araki T, Teshima K, Nakano H, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S.
    Vox Sang; 2003 Nov 04; 85(4):290-9. PubMed ID: 14633255
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.